Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study

被引：0
|
作者：
Nicolucci, A. [1 ]
Gomes, M. B. [2 ]
Khunti, K. [3 ]
Kosiborod, M. [4 ]
Pocock, S. [5 ]
Rathmann, W. [6 ]
Shestakova, M. V. [7 ]
Shimomura, I. [8 ]
Watada, H. [9 ]
Chen, H. [10 ]
Cid-Ruzafa, J. [11 ]
Fenici, P. [12 ]
Hammar, N. [13 ]
Tang, F. [4 ]
Ji, L. [14 ]
机构：
[1] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[2] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
[3] Univ Leicester, Leicester, Leics, England
[4] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[5] London Sch Hyg & Trop Med, London, England
[6] German Diabet Ctr, Dusseldorf, Germany
[7] Diabet Inst, Endocrinol Res Ctr, Moscow, Russia
[8] Osaka Univ, Osaka, Japan
[9] Juntendo Univ, Tokyo, Japan
[10] AstraZeneca, Gaithersburg, MD USA
[11] Evidera, Barcelona, Spain
[12] AstraZeneca, Cambridge, England
[13] AstraZeneca Gothenburg, Molndal, Sweden
[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：S173 / S174
页数：2
相关论文
共 50 条
  • [11] Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme
    Khunti, Kamlesh
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Kosiborod, Mikhail
    Pocock, Stuart
    Shestakova, Marina, V
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Nicolucci, Antonio
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 66 - 78
  • [12] Impact of early or late intensification of glucose-lowering therapy in patients with type 2 diabetes: the global DISCOVER study
    Ramirez, L.
    Ji, L.
    Bonnet, F.
    Chen, H.
    Cooper, A.
    Hammar, N.
    Leigh, P.
    Saraiva, G. L.
    Medina, J.
    Nicolucci, A.
    Rathmann, W.
    Shestakova, M. V.
    Surmont, F.
    Tang, F.
    Watada, H.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S148 - S149
  • [13] Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes?
    Jacobsen, Soren L.
    Kohler-Forsberg, Ole
    Rohde, Christopher
    SCHIZOPHRENIA RESEARCH, 2024, 270 : 231 - 234
  • [14] HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study
    Bongaerts, Brenda
    Kuss, Oliver
    Bonnet, Fabrice
    Chen, Hungta
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Khunti, Kamlesh
    Medina, Jesus
    Nicolucci, Antonio
    Shestakova, Marina V.
    Watada, Hirotaka
    Rathmann, Wolfgang
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1890 - 1899
  • [15] Durability of Second-Line Oral Glucose-Lowering Therapy in Type 2 Diabetes: Results of a Large UK Cohort Study
    Mamza, Jil
    Mehta, Raj
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2015, 64 : A39 - A39
  • [16] Are patients with schizophrenia treated less with second-line glucose-lowering drugs for type 2 diabetes? Response
    Bennett, Melanie E.
    Calkins, Monica E.
    Dickerson, Faith
    Kreyenbuhl, Julie
    Medoff, Deborah
    SCHIZOPHRENIA RESEARCH, 2024, 270 : 235 - 236
  • [17] Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER
    Nicolucci, Antonio
    Chen, Hungta
    Cooper, Andrew
    Gomes, Marilia B.
    Ji, Linong
    Khunti, Kamlesh
    Kosiborod, Mikhail N.
    Leigh, Paul
    Ramirez, Larisa
    Shestakova, Marina V.
    Shimomura, Iichiro
    Siddiqui, Afrah
    Tang, Fengming
    Vora, Jiten
    Watada, Hirotaka
    Arnold, Suzanne V.
    DIABETES, 2020, 69
  • [18] Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
    Bongaerts, Brenda
    Arnold, Suzanne, V
    Charbonnel, Bernard H.
    Chen, Hungta
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia
    Ji, Linong
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Medina, Jesus
    Nicolucci, Antonio
    Shestakova, Marina
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Rathmann, Wolfgang
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [19] Individualised HbA1c targets in people with type 2 diabetes initiating second-line therapy: the global DISCOVER study
    Khunti, K.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Hammar, N.
    Kennedy, K. F.
    Pocock, S.
    Shestakova, M. V.
    Shimomura, I.
    Surmont, F.
    Ji, L.
    DIABETOLOGIA, 2018, 61 : S175 - S175
  • [20] Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study
    Nicolucci, Antonio
    Chen, Hungta
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Medin, Jennie
    Shestakova, Marina, V
    Shimomura, Iichiro
    Tang, Fengming
    Vora, Jiten
    Watada, Hirotaka
    Arnold, Suzanne, V
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 185
12345